npj Precision Oncology (Feb 2024)
Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma
- Chiara Chiavelli,
- Malvina Prapa,
- Giulia Rovesti,
- Marco Silingardi,
- Giovanni Neri,
- Giuseppe Pugliese,
- Lucia Trudu,
- Massimiliano Dall’Ora,
- Giulia Golinelli,
- Giulia Grisendi,
- Jonathan Vinet,
- Marco Bestagno,
- Carlotta Spano,
- Roberto Vito Papapietro,
- Roberta Depenni,
- Katia Di Emidio,
- Anna Pasetto,
- Daniela Nascimento Silva,
- Alberto Feletti,
- Silvia Berlucchi,
- Corrado Iaccarino,
- Giacomo Pavesi,
- Massimo Dominici
Affiliations
- Chiara Chiavelli
- Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia
- Malvina Prapa
- Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia
- Giulia Rovesti
- Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia
- Marco Silingardi
- Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia
- Giovanni Neri
- Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia
- Giuseppe Pugliese
- Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia
- Lucia Trudu
- Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia
- Massimiliano Dall’Ora
- Evotec (Modena) Srl, Medolla
- Giulia Golinelli
- Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia
- Giulia Grisendi
- Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia
- Jonathan Vinet
- Centro Interdipartimentale Grandi Strumenti (CIGS), University of Modena and Reggio Emilia
- Marco Bestagno
- International Centre for Genetic Engineering and Biotechnology
- Carlotta Spano
- Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia
- Roberto Vito Papapietro
- Department of Oncology and Hematology, University-Hospital of Modena and Reggio Emilia
- Roberta Depenni
- Department of Oncology and Hematology, University-Hospital of Modena and Reggio Emilia
- Katia Di Emidio
- Department of Oncology and Hematology, University-Hospital of Modena and Reggio Emilia
- Anna Pasetto
- Section for Cell Therapy, Radiumhospitalet, Oslo University Hospital
- Daniela Nascimento Silva
- Department of Laboratory Medicine, Karolinska Institutet
- Alberto Feletti
- Department of Neurosciences, Biomedicine and Movement Sciences, Neurosurgery Unit, University of Verona
- Silvia Berlucchi
- Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia - Division of Neurosurgery, Department of Neurosciences, University-Hospital of Modena and Reggio Emilia
- Corrado Iaccarino
- Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia - Division of Neurosurgery, Department of Neurosciences, University-Hospital of Modena and Reggio Emilia
- Giacomo Pavesi
- Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia - Division of Neurosurgery, Department of Neurosciences, University-Hospital of Modena and Reggio Emilia
- Massimo Dominici
- Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia
- DOI
- https://doi.org/10.1038/s41698-024-00506-z
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 9
Abstract
Abstract Glioblastoma (GBM) remains a deadly tumor. Treatment with chemo-radiotherapy and corticosteroids is known to impair the functionality of lymphocytes, potentially compromising the development of autologous CAR T cell therapies. We here generated pre-clinical investigations of autologous anti-GD2 CAR T cells tested against 2D and 3D models of GBM primary cells. We detected a robust antitumor effect, highlighting the feasibility of developing an autologous anti-GD2 CAR T cell-based therapy for GBM patients.
